| TA185 |
Soft tissue sarcoma - trabectedin (TA185) |
|
-
-
Trabectedin for the treatment of advanced soft tissue sarcoma
Trabectedin is recommended as a possible treatment for people with advanced soft tissue sarcoma if:
- treatment with anthracyclines and ifosfamide has failed, or
- they cannot tolerate anthracyclines and ifosfamide, or
- anthracyclines and ifosfamide are unsuitable.
The manufacturer of trabectedin has agreed to a 'patient access scheme', which means that when a person needs more than five trabectedin treatments, it provides the sixth and any further trabectedin treatments to the NHS free of charge.
-
Other information
How this guidance was produced
Background information
- None found
This page was last updated: 08 December 2010
-
Guidance formats
-
Implementation tools and resources
See this guidance in practice
Patient
The summary of the key recommendations in the guidance written for patients, carers and those with little medical knowledge and may be used in local patient information leaflets.
Quick Reference Guide
The quick reference guide presents recommendations for health professionals
NICE Guidance
The published NICE clinical guidance, contains the recommendations for health professionals and NHS bodies.
Full Guidance
The published full clinical guidance for specialists with background, evidence, recommendations and methods used.
